Ascendis Pharma A/S

Ascendis Pharma A/S

95.22
BRL
+0.81
(+0.86%)
4.80EPS
15.49P/E
82.81BMarket Cap
Feb 17Next Earn

Total Valuation

BRL

As of September 30, 2026, Ascendis Pharma A/S ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR carries a market capitalization of 82.81B, placing it among publicly traded companies globally. Its enterprise value stands at 79.78B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap82.81B
Enterprise Value79.78B

Important Dates

Ascendis Pharma A/S ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR's next confirmed earnings release is scheduled for February 17, 2027.

Earnings Date2/17/2027

Share Statistics

As of September 30, 2026, Ascendis Pharma A/S ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR has 1.07B shares outstanding.

Shares Outstanding1.07B

Valuation Ratios

As of September 30, 2026, Ascendis Pharma A/S ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR trades at a trailing price-to-earnings ratio of 15.49. The price-to-sales ratio is 11.29, and the price-to-book ratio stands at 9.40.

PE Ratio15.49
PS Ratio11.29
PB Ratio9.40
P/TBV Ratio9.42
P/FCF Ratio26.62
P/OCF Ratio25.34

Enterprise Valuation

As of September 30, 2026, Ascendis Pharma A/S ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR trades at an EV/EBITDA multiple of 34.13 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 11.29 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 35.77 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 79.78B versus a market cap of 82.81B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales11.29
EV / EBITDA34.13
EV / EBIT35.77

Financial Position

As of September 30, 2026, Ascendis Pharma A/S ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR maintains a current ratio of 2.89, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 29.84, indicating elevated leverage, while an interest coverage ratio of 3.49 demonstrates adequate ability to service its debt obligations.

Current Ratio2.89
Quick Ratio2.22
Debt / Equity29.84
Debt / EBITDA1.13
Interest Coverage3.49

Financial Efficiency

These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) stands at 48.95, measuring how efficiently the asset base is converted into earnings. Inventory turnover of 0.31 indicates how many times Ascendis Pharma A/S ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)48.95
Inventory Turnover0.31

Taxes

BRL

Over the twelve months ended September 30, 2026, Ascendis Pharma A/S ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR recorded an income tax benefit of -3.57B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 1.58B, leaving 5.15B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax-3.57B

Stock Price Statistics

BRL

As of the close on November 9, 2026, Ascendis Pharma A/S ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR's stock has gained approximately 35.62% over the past 52 weeks. The 50-day moving average sits at 81.24, while the 200-day moving average is 53.66.

52-Week Price Change35.62%
50-Day Moving Average81.24
200-Day Moving Average53.66

Income Statement

BRL

Over the twelve months ended September 30, 2026, Ascendis Pharma A/S ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR generated 7.07B in revenue and converted that into 5.15B in net income, yielding earnings per share of 4.80. EBITDA reached 2.34B, while operating income came in at 2.21B.

Revenue7.07B
Gross Profit6.50B
Operating Income2.21B
Pretax Income1.58B
Net Income5.15B
EBITDA2.34B
EBIT2.23B
Earnings Per Share (EPS)4.80

Balance Sheet

BRL

As of September 30, 2026, Ascendis Pharma A/S ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR holds 5.66B in cash and equivalents against 2.63B in total debt, resulting in a net debt position of -3.03B. Total book value stands at 8.81B, with working capital of 6.10B providing operational flexibility.

Cash & Cash Equivalents5.66B
Total Debt2.63B
Net Debt-3.03B
Equity (Book Value)8.81B
Book Value Per Share8.21
Working Capital6.10B

Cash Flow

BRL

Ascendis Pharma A/S ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR produced 3.15B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -36.15M in capital expenditures, free cash flow totaled 3.11B - equivalent to 3.01 per share.

Operating Cash Flow3.15B
Capital Expenditures-36.15M
Free Cash Flow3.11B
FCF Per Share3.01

Margins

Over the twelve months ended September 30, 2026, Ascendis Pharma A/S ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR posted a gross margin of 91.93, reflecting its pricing power and cost economics. The operating margin of 31.28 and net profit margin of 72.88 provide insight into operational efficiency.

Gross Margin91.93
Operating Margin31.28
Pretax Margin22.33
Profit Margin72.88
EBITDA Margin33.08

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield stands at 3.76, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.80, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Ascendis Pharma A/S ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR shareholders.

Shareholder Yield0.80
FCF Yield3.76